Product Description
Gabapentin enacarbil is used to treat moderate-to-severe primary Restless Legs Syndrome (RLS). RLS is a neurologic disorder that makes the legs feel uncomfortable. This results in an irresistible feeling of wanting to move your legs to make them comfortable. (Sourced from: https://www.mayoclinic.org/drugs-supplements/gabapentin-enacarbil-oral-route/description/drg-20122596)
Mechanisms of Action: Calcium Channel Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Egypt | Japan | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/08/2023 |
News Article |
Heartbeat Executive Creative Director Kris LoCascio Honored as "Agency Vanguard" Award Winner by Xpectives.Health |
|
10/24/2022 |
News Article |
Heartbeat Names Kris LoCascio New Executive Creative Director |
|
10/24/2022 |
News Article |
Heartbeat Names Kris LoCascio New Executive Creative Director |
|
05/24/2022 |
News Article |
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer |